6 completed, 4 unknown, 3 active not recruiting, 3 recruiting. 18 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 6, Unknown 4, Active not recruiting 3, Recruiting 3, Not yet recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Langerhans Cell Histiocytosis: new trials by email Literature Review of Langerhans Cell Histiocytosis trials Research Report on Langerhans Cell Histiocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis Luvometinib, Luvometinib, Cytarabine. - Langerhans Cell Histiocytosis | Phase 2 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 30 | 2026-06-30 | 2026-07-27 |
| Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH Cytarabine (Ara-C), Thalidomide (100mg) - Langerhans Cell Histiocytosis | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 50 | 2025-04-12 | 2025-09-22 |
| Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib Trametinib - Langerhans Cell Histiocytosis | Phase 2 | Recruiting | Cook Children's Health Care System | 75 | 2024-06-24 | 2026-04-07 |
| To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH FCN-159 - Langerhans Cell Histiocytosis, LCH | Phase 2 | Recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 56 | 2023-09-28 | 2025-01-24 |
| The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation HLX208 - Langerhans Cell Histiocytosis, Erdheim-Chester Disease | Phase 2 | Unknown | Shanghai Henlius Biotech | 25 | 2021-12-06 | 2023-08-08 |
| Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis thalidomide combined with dexamethasone and cyclophosphamide - Langerhans Cell Histiocytosis | Phase 2 | Unknown | Peking Union Medical College Hospital | 20 | 2019-10-10 | 2021-06-08 |
| AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis Cytarabine - Langerhans Cell Histiocytosis | Phase 2 | Unknown | Peking Union Medical College Hospital | 40 | 2019-10-01 | 2021-06-08 |
| A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation Vemurafenib, Cytarabine, 2-chlorodeoxyadenosine - Langerhans Cell Histiocytosis | Phase 2 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 12 | 2018-06-26 | 2023-03-16 |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Vemurafenib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2017-11-08 | 2025-01-27 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Anti-Thymocyte Globulin, Busulfan, Clofarabine - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 6 | 2017-10-13 | 2023-10-11 |
| Denosumab for the Treatment of Adult LCH Denosumab 70 MG/ML [Xgeva] - Langerhans Cell Histiocytosis | Phase 2 | Completed | Hellenic Society for the Study of Bone Metabolism | 10 | 2017-09-07 | 2025-01-15 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Prednisone, Vinblastine, mercaptopurine - Langerhans Cell Histiocytosis | Phase 2 / Phase 3 | Active not recruiting | North American Consortium for Histiocytosis | 1400 | 2016-11-02 | 2026-04-09 |
| Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders Clofarabine - Langerhans Cell Histiocytosis | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 25 | 2015-05-01 | 2026-06-23 |
| Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis methotrexate - Langerhans Cell Histiocytosis | Phase 2 | Completed | Peking Union Medical College Hospital | 43 | 2014-01-01 | 2026-09-21 |
| A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis GSK2110183 - Langerhans Cell Histiocytosis | Phase 2 | Completed | GlaxoSmithKline | 17 | 2011-11-01 | 2020-09-09 |
| Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH Methotrexate, 6-Thioguanine, Leucovorin Calcium - Langerhans Cell Histiocytosis | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 5 | 1995-01-01 | 2015-05-04 |
| Clofarabine for Langerhans in Pedi Clofarabine - Langerhans Cell Histiocytosis | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2015-08-25 |
Histiocytosis, Langerhans-Cell (18) · Lymphoma, Non-Hodgkin (3) · Central Nervous System Neoplasms (2) · Ependymoma (2) · Glioma (2) · Hepatoblastoma (2) · Neuroblastoma (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Osteosarcoma (2) · Rhabdoid Tumor (2) · Rhabdomyosarcoma (2) · Sarcoma (2) · Sarcoma, Ewing (2) · Wilms Tumor (2) · Anemia, Refractory, with Excess of Blasts (1)
Hemic and Lymphatic Diseases (18) · Lung Diseases (18) · Lung Diseases, Interstitial (18) · Lymphatic Diseases (18) · Respiratory Tract Diseases (18) · Histiocytosis (17) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Disease Attributes (2) · Female Urogenital Diseases (2)
Cytarabine (6) · Clofarabine (3) · Methotrexate (3) · Vemurafenib (3) · Cladribine (2) · Cyclophosphamide (2) · Antilymphocyte Serum (1) · Biopsy (1) · Busulfan (1) · CCT239065 (1) · CT-P10 (1) · Cord Blood Stem Cell Transplantation (1) · Denosumab (1) · Dexamethasone (1) · Filgrastim (1)
Peking Union Medical College Hospital (3) · Dana-Farber Cancer Institute (2) · National Cancer Institute (NCI) (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Cook Children's Health Care System (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · GlaxoSmithKline (1) · Hellenic Society for the Study of Bone Metabolism (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · North American Consortium for Histiocytosis (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · Shanghai Henlius Biotech (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)
United States (8) · China (7) · Canada (2) · Puerto Rico (2) · Australia (1) · Greece (1) · Russia (1)
AeRang Kim (1) · Amanda Olson (1) · Anish Ray, MD (1) · Barbara Degar, MD (1) · Carlos Rodriguez-Galindo, MD (1) · Donald W Parsons (1) · Jian Li (1) · Jian Li, MD (1) · Milen Minkov, MD, Ph.D (1) · Polyzois Makras, MD, PhD (1) · Rui Zhang, MD (1) · Shannon R Morris, MD, PhD (1) · Tanya Trippett, MD (1) · Xinxin XX Cao, doctor (1)
PMID 31401903, PMID 32423455, PMID 33591402, PMID 35353553, PMID 37216396, PMID 38873934, PMID 41166674, PMID 42126265, PMID 42686334
U10CA180886 (2)